Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
1 study found for:    8725145 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Terminated
Has Results 		Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)
Conditions: Hypertriglyceridemia in Type 4 Hyperlipidemia;   Non Diabetic Subjects With Normoglycemia
Interventions: Drug: Rosiglitazone;   Drug: Placebo (Rosiglitazone);   Drug: Placebo (Fenofibrate);   Drug: Fenofibrate
To Top

† Indicates status has not been verified in more than two years